← Back to Search

Other

Atrantil (Medical Food) for Irritable Bowel Syndrome

N/A
Waitlist Available
Led By Darren Brenner, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-treatment (+-3 days)
Awards & highlights

Study Summary

This trial will study the effects of a supplement called Atrantil on people with too much bacteria in their gastrointestinal tract. This condition, called Intestinal Bacterial Overgrowth (IBO), can cause symptoms like abdominal pain, bloating, diarrhea, and constipation. The investigators hope that Atrantil will help relieve these symptoms and improve quality of life for people with IBO.

Eligible Conditions
  • Small Intestinal Bacterial Overgrowth
  • Irritable Bowel Syndrome
  • Bacterial Overgrowth Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline at four weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline at four weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in clinical symptoms of Intestinal Methane Overgrowth as measured by Patient Reported Outcome Measures Information Systems Gastrointestinal Symptoms Scale (PROMIS-GI)
Change in clinical symptoms of Intestinal Methane Overgrowth as measured by daily Numeric Rating Scale (NRS) measuring pain, bloating, distention, and discomfort.
Change in clinical symptoms of Intestinal Methane Overgrowth as measured by the Bristol Stool Scale (BSS)
Secondary outcome measures
Change in Quality of life as measured by the PROMIS-Global Health (PROMIS-GH)
Change in methane as measured by hydrogen methane breath-test pre and post-treatment.
Change in quality of life as measured by Short Form- 12.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental: Atrantil (Medical Food)Experimental Treatment1 Intervention
All participants in the trial will take two capsules of Atrantil three times a day for 28 days.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,586 Previous Clinical Trials
917,211 Total Patients Enrolled
Darren Brenner, MD3.151 ReviewsPrincipal Investigator - Northwestern Memorial Hospital/Feinberg School of Medicine
Northwestern University
5Patient Review
I highly recommend this endoscopist/colonoscopist. They're the best I've ever had.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are investigators presently enrolling participants in this experiment?

"As per the clinicaltrials.gov database, this medical research is not looking for recruits at present. The trial was first publicized on September 18th 2020 and last amended on August 30th 2021. Nevertheless, there are 1,422 other studies actively seeking participants right now."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Atrantil for Intestinal Bacterial Overgrowth
Darren Brenner 2020. "Atrantil for Intestinal Bacterial Overgrowth". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04755673.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top